Initially, it was shown that the clinical activity of the monoclonal antibody pembrolizumab, by blocking programmed cell death 1 (PD1) on T cells and other immune cell populations, enhanced the cytotoxic killing of tumor cells, improving survival rates in metastatic MSI CRCs [118,119,120]. The gene discussed is PDCD1; the disease is neoplasm.